PRESS RELEASE Pharmacists in hospitals across the U.
4 % of hospitals to verify patient identification and electronically check doses administered by nurses. In comparison, only 34 to 65.8 % of hospitals used BCMA in 2011. Mid-size hospitals experienced the highest usage of BCMA, while little hospitals had the lowest use of BCMA. Electronic Wellness Record Systems Overall, 94.1 % of hospitals possess partially or completely implemented an EHR. The usage of EHR systems has increased since 2009 among hospitals of most sizes, with growth ranging from 6.9 to 42.4 %. Computerized Prescriber-Order-Entry Systems CPOE systems are found in 80.9 % of hospitals. In hospitals of all sizes, growth in CPOE systems since 2009 offers ranged from 35.4 % to 76.2 %. In the July 1 issue of AJHP The survey report appears.These data offer clear proof the biologic activity of bevacizumab, with a maximum improvement in progression-free survival of around 15 percent at 12 months, which disappeared by 24 months. The restricted suggest difference summarized the treatment impact for the nonproportional hazards detected and showed an improvement in the mean progression-free survival of 1 1.5 to 2 months with bevacizumab. The progression-free survival and general survival benefits were much greater among the sufferers at risky for progression than among patients at lower risk. Both the timing of the maximal treatment impact, which coincided with the end of planned bevacizumab treatment , and the larger treatment effect seen in women with an increase of advanced disease, who were more likely to get bevacizumab to enough time of disease progression up, are intriguing and raise the possibility that prolonged therapy beyond 12 months, until disease progression perhaps, might improve the outcome further.